Compare Duolingo Inc (DUOL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Duolingo IncTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Duolingo Inc trades at $134 (market cap $6.34B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.2× Duolingo Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

	DUOL	VRTX
Market Cap	$6.34B	$134.25B
Sector	Technology	Health
52-Week High	$369.19	$529.65
52-Week Low	$90.03	$376.62
Enterprise Value	$5.11B	$128.37B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DUOL

Duolingo remains a Hold due to slowing growth and high valuation despite strong cash flow.Seeking Alpha · 1 day agoNeutral Duolingo downgraded to Neutral as revenue growth lags behind strong user gainsSeeking Alpha · 2 days agoBearish View details →

VRTX

View details →

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.